250 related articles for article (PubMed ID: 25753634)
1. Risk factors for recurrence after successful treatment of Mycobacterium avium complex lung disease.
Lee BY; Kim S; Hong Y; Lee SD; Kim WS; Kim DS; Shim TS; Jo KW
Antimicrob Agents Chemother; 2015; 59(6):2972-7. PubMed ID: 25753634
[TBL] [Abstract][Full Text] [Related]
2. Association Between Duration of Aminoglycoside Treatment and Outcome of Cavitary Mycobacterium avium Complex Lung Disease.
Kim OH; Kwon BS; Han M; Koh Y; Kim WS; Song JW; Oh YM; Lee SD; Lee SW; Lee JS; Lim CM; Choi CM; Huh JW; Hong SB; Shim TS; Jo KW
Clin Infect Dis; 2019 May; 68(11):1870-1876. PubMed ID: 30239615
[TBL] [Abstract][Full Text] [Related]
3. Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease.
Jeong BH; Jeon K; Park HY; Kim SY; Lee KS; Huh HJ; Ki CS; Lee NY; Shin SJ; Daley CL; Koh WJ
Am J Respir Crit Care Med; 2015 Jan; 191(1):96-103. PubMed ID: 25393520
[TBL] [Abstract][Full Text] [Related]
4. Clinical Characteristics, Treatment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant Mycobacterium avium Complex Lung Disease.
Moon SM; Park HY; Kim SY; Jhun BW; Lee H; Jeon K; Kim DH; Huh HJ; Ki CS; Lee NY; Kim HK; Choi YS; Kim J; Lee SH; Kim CK; Shin SJ; Daley CL; Koh WJ
Antimicrob Agents Chemother; 2016 Nov; 60(11):6758-6765. PubMed ID: 27572413
[TBL] [Abstract][Full Text] [Related]
5. Intermittent Antibiotic Therapy for Recurrent Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease.
Jhun BW; Moon SM; Kim SY; Park HY; Jeon K; Kwon OJ; Huh HJ; Ki CS; Lee NY; Chung MJ; Lee KS; Shin SJ; Daley CL; Koh WJ
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203483
[TBL] [Abstract][Full Text] [Related]
6. Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease.
Wallace RJ; Brown-Elliott BA; McNulty S; Philley JV; Killingley J; Wilson RW; York DS; Shepherd S; Griffith DE
Chest; 2014 Aug; 146(2):276-282. PubMed ID: 24457542
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of intermittent maintenance therapy after successful treatment of Mycobacterium avium complex lung disease.
Asakura T; Nakagawa T; Suzuki S; Namkoong H; Morimoto K; Ishii M; Kurashima A; Betsuyaku T; Ogawa K; Hasegawa N;
J Infect Chemother; 2019 Mar; 25(3):218-221. PubMed ID: 30172726
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics and treatment outcomes of patients with macrolide-resistant Mycobacterium avium complex pulmonary disease: a systematic review and meta-analysis.
Park Y; Lee EH; Jung I; Park G; Kang YA
Respir Res; 2019 Dec; 20(1):286. PubMed ID: 31852452
[TBL] [Abstract][Full Text] [Related]
9. Mycobacterium avium complex pulmonary disease: management options in HIV-negative patients.
Ramirez J; Mason C; Ali J; Lopez FA
J La State Med Soc; 2008; 160(5):248-54; quiz 254, 293. PubMed ID: 19048978
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Treatment Outcomes of Cavitary Mycobacterium avium Complex Pulmonary Disease with Streptomycin or Amikacin Use.
Kim SM; Chong YP; Lee HJ; Shim TS; Jo KW
Microbiol Spectr; 2023 Jun; 11(3):e0474122. PubMed ID: 37022189
[TBL] [Abstract][Full Text] [Related]
11. Development of Macrolide Resistance and Reinfection in Refractory Mycobacterium avium Complex Lung Disease.
Jhun BW; Kim SY; Moon SM; Jeon K; Kwon OJ; Huh HJ; Ki CS; Lee NY; Shin SJ; Daley CL; Koh WJ
Am J Respir Crit Care Med; 2018 Nov; 198(10):1322-1330. PubMed ID: 29877739
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Mycobacterium avium Complex (MAC).
Griffith DE
Semin Respir Crit Care Med; 2018 Jun; 39(3):351-361. PubMed ID: 30071550
[No Abstract] [Full Text] [Related]
13. Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease.
Hayashi M; Takayanagi N; Kanauchi T; Miyahara Y; Yanagisawa T; Sugita Y
Am J Respir Crit Care Med; 2012 Mar; 185(5):575-83. PubMed ID: 22199005
[TBL] [Abstract][Full Text] [Related]
14. The second recurrence of
Kwon BS; Shim TS; Jo KW
Eur Respir J; 2019 Jan; 53(1):. PubMed ID: 30337449
[No Abstract] [Full Text] [Related]
15. Treatment Outcomes of Cavitary Nodular Bronchiectatic-Type Mycobacterium avium Complex Pulmonary Disease.
Chae G; Park YE; Chong YP; Lee HJ; Shim TS; Jo KW
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0226121. PubMed ID: 35950842
[TBL] [Abstract][Full Text] [Related]
16. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease.
Griffith DE; Brown-Elliott BA; Langsjoen B; Zhang Y; Pan X; Girard W; Nelson K; Caccitolo J; Alvarez J; Shepherd S; Wilson R; Graviss EA; Wallace RJ
Am J Respir Crit Care Med; 2006 Oct; 174(8):928-34. PubMed ID: 16858014
[TBL] [Abstract][Full Text] [Related]
17. Treatment outcomes of refractory MAC pulmonary disease treated with drugs with unclear efficacy.
Jo KW; Kim S; Lee JY; Lee SD; Kim WS; Kim DS; Shim TS
J Infect Chemother; 2014 Oct; 20(10):602-6. PubMed ID: 24981714
[TBL] [Abstract][Full Text] [Related]
18. Serial CT findings of nodular bronchiectatic Mycobacterium avium complex pulmonary disease with antibiotic treatment.
Lee G; Kim HS; Lee KS; Koh WJ; Jeon K; Jeong BH; Ahn J
AJR Am J Roentgenol; 2013 Oct; 201(4):764-72. PubMed ID: 24059365
[TBL] [Abstract][Full Text] [Related]
19. The natural history of non-cavitary nodular bronchiectatic Mycobacterium avium complex lung disease.
Kwon BS; Lee JH; Koh Y; Kim WS; Song JW; Oh YM; Lee SD; Lee SW; Lee JS; Lim CM; Choi CM; Huh JW; Hong SB; Shim TS; Jo KW
Respir Med; 2019 Apr; 150():45-50. PubMed ID: 30961950
[TBL] [Abstract][Full Text] [Related]
20. Determinants of recurrence after successful treatment of Mycobacterium avium complex lung disease.
Min J; Park J; Lee YJ; Kim SJ; Park JS; Cho YJ; Yoon HI; Lee CT; Lee JH
Int J Tuberc Lung Dis; 2015 Oct; 19(10):1239-45. PubMed ID: 26459540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
